StockDrifts LogoStockDrifts

Sig Medtech 056090

Company
시지메드텍Sig Medtech
Insiders
1
Buys
2
Total Value
₩10M ($7K)
Avg Return
+75.17%
Last Filing
2026-01-13

Sig Medtech (056090) has 2 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩10M ($7K) in reported transaction value. The earliest filing StockDrifts holds for Sig Medtech is dated 2024-02-07; the most recent is 2026-01-13. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +75.17%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-01-13BUY회사분할
시지바이오
CG Bio
-9.2M₩1,401+109.1%₩12.9B ($8.9M)
2026-01-13SELL회사분할
시지바이오
CG Bio
--9.2M₩1,401-109.1%₩12.9B ($8.9M)
2026-01-12SELL회사분할
시지바이오
CG Bio
--32.6M₩1,381-112.2%₩45.0B ($31.2M)
2026-01-12BUY회사분할
시지바이오
CG Bio
-32.6M₩1,381+112.2%₩45.0B ($31.2M)
2024-10-31BUY제3자배정유상증자
시지바이오
CG Bio
-9.2M₩1,331+120.1%₩12.2B ($8.5M)
2024-06-14BUYMarket Buy
정주미
Joomi Jeong
CEO3.0K₩1,527+91.9%₩5M ($3K)
2024-06-11BUYMarket Buy
정주미
Joomi Jeong
CEO3.0K₩1,849+58.5%₩6M ($4K)
2024-02-16BUY장외매수
시지바이오
CG Bio
-4.6M₩2,360+24.1%₩10.8B ($7.5M)
2024-02-14BUY유상신주취득
시지바이오
CG Bio
-14.0M₩2,360+24.1%₩33.0B ($22.9M)
2024-02-07BUY장외매수
시지바이오
CG Bio
-14.0M₩2,360+24.1%₩33.0B ($22.9M)

Frequently asked questions

Who has been buying Sig Medtech stock?
1 distinct insiders have filed 2 disclosed insider purchases in Sig Medtech (056090), most recently on 2026-01-13. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Sig Medtech have?
Sig Medtech has 2 buy-side and 0 sell-side disclosures on record, covering ₩10M ($7K) in total reported value, spanning 2024-02-07 to 2026-01-13.
Where does StockDrifts get Sig Medtech insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Sig Medtech. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.